Myeloma Therapy

1. Front Matter

   Pages i-xvi

   PDF

2. Biologic Consideration and Myeloma

   1. Staging in Multiple Myeloma

      • Leonard T. Heffner

      Pages 3-7

   2. Epidemiology of Multiple Myeloma

      • Amelia A. Langston, Dixil Francis

      Pages 9-22

   3. Basic Biology of Plasma Cell Dyscrasias: Focus on the Role of the Tumor Microenviroment

      • Marc S. Raab, Kenneth C. Anderson

      Pages 23-39

   4. Biology-Based Classification and Staging of Multiple Myeloma

      • Wee Joo Chng, Peter Leif Bergsagel

      Pages 41-56

   5. Cytogenetic Abnormalities in Multiple Myeloma: The Importance of FISH and Cytogenetics

      • Esteban Braggio, Michael Sebag, Rafael Fonseca

      Pages 57-76

3. Historical and Cytotoxic Agent-Based Therapies for Myeloma

   1. Role of Autologous Stem Cell Transplantation in Multiple Myeloma

      • Jean-Luc Harousseau

      Pages 79-90

   2. Maintenance Therapy in Multiple Myeloma

      • Jonathan L. Kaufman, Ronald Mihelic, Sagar Lonial

      Pages 91-98

   3. Therapy for Patients not Eligible for Autologous Transplant

      • Bringhen Sara, Palumbo Antonio

      Pages 99-112

   4. Current Role of Anthracyclines in the Treatment of Multiple Myeloma

      • Sikander Ailawadhi, Asher Chanan-Khan

      Pages 113-121

4. Immune-Based Therapies

   1. Allogeneic Transplantation for Multiple Myeloma

      • Fengrong Wang, Edmund K. Waller

      Pages 125-142

   2. Immunobiology and Immunotherapy of Multiple Myeloma

      • Madhav V. Dhodapkar

      Pages 143-166

   3. Antibody and Other Immune-Based Therapies for Myeloma

      • Nikhil C. Munshi, Yu-Tzu Tai

      Pages 167-202

5. Existing Novel Agents

   1. Thalidomide in Patients with Relapsed Multiple Myeloma

      • Ashraf Badros

      Pages 205-227

   2. Thalidomide: Induction Therapy

      • Francis K. Buadi, S. Vincent Rajkumar

      Pages 229-237

   3. The Role of Bortezomib in the Treatment of Relapsed and Refractory Multiple Myeloma

      • Paul G. Richardson, Constantine S. Mitsiades, Robert Schlossman, Teru Hideshima, Irene Ghobrial, Nikhil C. Munshi et al.

      Pages 239-252

   4. Bortezomib as Induction Therapy in Patients with Multiple Myeloma

      • San J. F. Miguel, M. V. Mateos

      Pages 253-263

   5. Lenalidomide in Relapsed or Refractory Multiple Myeloma

      • Sheeba K. Thomas, Tiffany A. Richards, Donna M. Weber

      Pages 265-277

   6. Lenalidomide for Initial Therapy of Newly Diagnosed Multiple Myeloma

      • Shaji Kumar

      Pages 279-288

6. Current and Future Targets

   1. The Role of Heat Shock Protein 90 as a Therapeutic Target for Multiple Myeloma

      • Constantine S. Mitsiades, Teru Hideshima, Nikhil C. Munshi, Paul G. Richardson, Kenneth C. Anderson

      Pages 291-308

Therapeutic options for patients with myeloma have dramatically changed over the past 10 years. Beginning with the advances in therapy resulting from the use of high-dose therapy and autologous bone marrow or stem cell tra- plant, we have more than doubled the median survival for patients as a whole, and have now have a wealth of different biology -based treatment approaches for our patients in all disease stages. This book represents state-of-the-art information from many of the leaders in the plasma cell disorders world. Sections focusing on disease pathogenesis and biology, chemotherapy-based approaches, immune -based therapies, currently approved novel agents, developing targets, supportive care, and other plasma cell disorders provides a comprehensive collection and an excellent resource in this time of rapid change in clinical and preclinical disease knowledge. It is important to realize that these changes did not occur in a vacuum. Partnerships between academic institutions, the pharmaceutical industry, patient advocacy groups, the National Cancer Institute, community onco- gists, and ultimately our patients worked closely together to realize these advances, and to effect the radical changes in therapy we have witnessed over the past few years. This book would not have been possible without contri- tions from each of the gifted scientists and clinicians who worked tirelessly to prepare their individual chapters all the while maintaining commitment to the scientific and clinical mission of advancing care.

• Angst
• Autologous Bone Marrow
• Bortezomib
• Chemotherapy
• Hematology
• Lenalidomide
• Myeloma
• Plasma cell
• Staging
• Thalidomide
• Therapeutic
• classification

From the reviews:

"The book Myeloma Therapy: Pursuing the Plasma Cell, edited by Sagar Lonial, arrives just in time. … a comprehensive, updated review of all the problems concerning myeloma. The authors are among the world’s top scientific leaders in this field … . Consultation and systematic reading are interesting, useful, and very agreeable. It cannot be lacking in the library of the hematologists and oncologists taking care of myeloma patients, and it’s also a worthwhile volume for scientists involved in preclinical research." (Sergio Storti, Laboratory Hematology, Vol. 15 (34), 2009)

“Myeloma therapy by Sagar Lonial deals with various aspects of the plasma cell disorders and multiple myeloma in particular. … this is a goldmine of information written in a style that is accessible to the biochemically interested clinician. … is highly recommended to the advanced reader in this field. It is a reference work on both clinical and biological aspects of multiple myeloma and should be part of the libraries of hospitals for physicians who are professionally frequently involved with the treatment of this disease.” (F. Offner, Acta Clinica Belgica, Vol. 65 (3), 2010)

• Winship Cancer Institute, Emory University, Atlanta, USA

  Sagar Lonial

Policies and ethics